Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia
Status:
Terminated
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
Phase 1, single-center, open-label, sequential cohort dose escalation study. This is a 3 + 3
design study involving at least 3 subjects in ascending dose cohorts, with subjects
participating up to 10 weeks.
The overall study objectives are to evaluate the safety and tolerability of TXA127 in
thrombocytopenic subjects with low or intermediate-1 risk MDS.
Evaluation of the platelet response and the erythroid and granulocytic responses to TXA127
will provide preliminary efficacy data.